S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

Q2 2022 EPS Estimates for Merus Raised by Analyst (NASDAQ:MRUS)

Last updated on Saturday, May 14, 2022 | 2022 MarketBeat

Merus (NASDAQ:MRUS - Get Rating) - Investment analysts at William Blair upped their Q2 2022 EPS estimates for Merus in a note issued to investors on Tuesday, May 10th. William Blair analyst M. Phipps now expects that the biotechnology company will earn ($0.62) per share for the quarter, up from their prior forecast of ($0.69). William Blair also issued estimates for Merus' Q3 2022 earnings at ($0.62) EPS, Q4 2022 earnings at ($0.63) EPS, FY2022 earnings at ($2.31) EPS, Q1 2023 earnings at ($0.65) EPS, Q2 2023 earnings at ($0.67) EPS, Q3 2023 earnings at ($0.73) EPS, Q4 2023 earnings at ($0.77) EPS, FY2023 earnings at ($2.83) EPS, FY2024 earnings at ($2.68) EPS, FY2025 earnings at ($2.10) EPS and FY2026 earnings at ($1.95) EPS.

Several other equities research analysts have also weighed in on MRUS. StockNews.com began coverage on Merus in a research report on Thursday, March 31st. They set a "hold" rating on the stock. Needham & Company LLC began coverage on Merus in a research report on Thursday, February 10th. They set a "buy" rating and a $45.00 target price on the stock. BMO Capital Markets began coverage on Merus in a research report on Friday, February 11th. They set an "outperform" rating and a $45.00 target price on the stock. HC Wainwright reissued a "buy" rating on shares of Merus in a research report on Tuesday. Finally, Zacks Investment Research raised Merus from a "hold" rating to a "buy" rating and set a $18.00 target price on the stock in a research report on Friday. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $37.78.


MRUS opened at $15.97 on Thursday. Merus has a one year low of $14.78 and a one year high of $33.09. The company has a market cap of $695.49 million, a P/E ratio of -8.54 and a beta of 1.11. The business's 50-day simple moving average is $24.49 and its 200-day simple moving average is $26.62. Merus (NASDAQ:MRUS - Get Rating) last issued its quarterly earnings results on Monday, February 28th. The biotechnology company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.24. Merus had a negative return on equity of 29.02% and a negative net margin of 143.77%. The company had revenue of $14.71 million for the quarter, compared to the consensus estimate of $12.39 million.

In other Merus news, EVP Peter B. Silverman sold 60,000 shares of Merus stock in a transaction that occurred on Thursday, March 10th. The stock was sold at an average price of $26.95, for a total value of $1,617,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 2.90% of the company's stock.

Several hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP grew its stake in shares of Merus by 134.9% in the 3rd quarter. Wellington Management Group LLP now owns 5,009,204 shares of the biotechnology company's stock valued at $110,201,000 after purchasing an additional 2,876,971 shares during the last quarter. Commodore Capital LP grew its stake in shares of Merus by 108.7% in the 4th quarter. Commodore Capital LP now owns 1,498,890 shares of the biotechnology company's stock valued at $47,665,000 after purchasing an additional 780,754 shares during the last quarter. BioImpact Capital LLC grew its stake in shares of Merus by 34.4% in the 3rd quarter. BioImpact Capital LLC now owns 941,948 shares of the biotechnology company's stock valued at $20,723,000 after purchasing an additional 241,069 shares during the last quarter. Lynx1 Capital Management LP purchased a new position in shares of Merus in the 4th quarter valued at approximately $24,912,000. Finally, Millennium Management LLC grew its stake in shares of Merus by 39.2% in the 4th quarter. Millennium Management LLC now owns 774,767 shares of the biotechnology company's stock valued at $24,638,000 after purchasing an additional 218,244 shares during the last quarter. Institutional investors own 85.32% of the company's stock.

About Merus (Get Rating)

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

Recommended Stories

Earnings History and Estimates for Merus (NASDAQ:MRUS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Merus right now?

Before you consider Merus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.

While Merus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.